| Choriocarcinoma and intraplacental choriocarcinoma | PSTT | ETT |
Fetus | - Varies: Absent in complete hydatidiform mole, but present for all others*
| - May follow antecedent pregnancy by months to years*
| - May follow antecedent pregnancy by months to years*
|
Cytotrophoblasts | - Atypical, highly proliferative*
| | |
Syncytiotrophoblasts | | | |
Implantation site extravillous (intermediate) trophoblasts | | | |
Chorionic membranous extravillous (intermediate) trophoblasts | | | |
Chorionic villi | | | |
Biological potential | | - Invasive and metastatic in approximately 30 to 50% of cases
| |
Differential diagnosis | - Non-gestational gonadal (ovarian) cell-derived choriocarcinoma
- Somatic high-grade malignant neoplasm
| - "Exaggerated" normal implantation site (Ki-67 proliferation index <5%)
- Atypical implantation site (Ki-67 proliferation index between 5 and 10%)
- Molar implantation site (molar chorionic villi present elsewhere)
- High-grade non-gestational epithelioid malignant neoplasm
- Rarely mixed PSTT and concurrent choriocarcinoma
| - Atypical placental site nodule (Ki-67 proliferation index between 5 and 10%)
- Cervical squamous cell carcinoma (when tumor arises in the cervix or lower uterine segment)
- High-grade non-gestational epithelioid malignant neoplasm
- Rarely mixed ETT and concurrent choriocarcinoma
|
Typical genetics | - Biparental disomy
- Diandric (46,XX) when derived from complete hydatidiform mole
| | |
Key marker status | - SALL4-positive; strong staining for beta-hCG in syncytiotrophoblasts
| - CD146 (Mel-CAM)- and hPL-positive, p63-negative, Ki-67 proliferation index >10%
| - CD146 (Mel-CAM)-negative or patchy, p63- and PLAP-positive, Ki-67 proliferation index >10%
|